Communicating an Adult Diagnosis of Cancer to Children

Nurses are a valuable resource to support and guide parents in communicating their cancer diagnosis with their children. This can result in improved relationships, better coping and less stress on the parent. With the proper training, nurses can facilitate this process while supporting and empowering parents in sharing this personal experience with their children.

Target Audience

This program is designed to meet the educational needs of oncology nurses who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Describe the importance of involving children in the communication of the parent’s diagnosis.
  • Provide examples of strategies to communicate a diagnosis of cancer to children and resources available to aid in the conversation.
  • Discuss opportunities to involve other members of the child’s multidisciplinary team (e.g., teachers, clergy, school counselor).
Additional information

This activity is supported by educational grants from:

  • AstraZeneca
  • Epizyme Inc.
  • Genentech, a member of the Roche Group
  • Novartis
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Pfizer Inc.
Course summary
Available credit: 
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
Course expires: 

The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute


NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 


Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

Presenting Faculty

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.



The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Amanda E. Visnick, RN, BSN, OCN

NCCN Staff Disclosures 

The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Crystal Denlinger, MD, FACP
Agios, Inc.: Grant/Research Support
Amgen Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Scientific Advisor; Grant/Research Support
Genmab: Grant/Research Support
MacroGenics: Grant/Research Support
MedImmune Inc: Grant/Research Support
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support

Samantha L. Tamburro, RN, BSN, CPON
Flatiron Health, Inc.: Salary

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NCCN designates this educational activity for a maximum of 1.0 contact hour.

Available Credit

  • 1.00 ANCC contact hours
  • 1.00 Participation


Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing